The role of chemotherapy in the modern management of melanoma
作者： Rebecca Jane Lee , Noor Ul-Ain-Tariq , Alberto Fusi , Samantha Bowyer , Paul Lorigan
DOI: 10.2217/MMT.14.20
关键词:
摘要: The treatment of malignant melanoma has changed beyond recognition in the last 7 years. Where previously single agent dacarbazine was often only used for advanced disease, now there are potentially multiple lines treatment, based on immunotherapy and targeted options, either as monotherapy or combination. In this brave new world question arises, does chemotherapy still have any relevance modern management melanoma? review, we summarize various chemotherapeutic options that been trialled to date, discuss role may play treating melanoma, combination with more novel agents, certain subtypes melanoma.
manchester.ac.uk参考文章(112)
P. Lemarbre, J. Ódonnell, L. H. Maurer, R. J. Forcier, S. A. Del Prete, Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma. Cancer treatment reports. ,vol. 68, pp. 1403- 1405 ,(1984)
Douglas Grossman, Dario C. Altieri, Drug resistance in melanoma: Mechanisms, apoptosis, and new potential therapeutic targets Cancer and Metastasis Reviews. ,vol. 20, pp. 3- 11 ,(2001) , 10.1023/A:1013123532723
Lila Adnane, Pamela A. Trail, Ian Taylor, Scott M. Wilhelm, Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature Methods in Enzymology. ,vol. 407, pp. 597- 612 ,(2006) , 10.1016/S0076-6879(05)07047-3
Kristina Buder, Anja Gesierich, Götz Gelbrich, Matthias Goebeler, Systemic treatment of metastatic uveal melanoma: review of literature and future perspectives Cancer Medicine. ,vol. 2, pp. 674- 686 ,(2013) , 10.1002/CAM4.133
Simon J Furney, Samra Turajlic, Gordon Stamp, Mahrokh Nohadani, Anna Carlisle, J Meirion Thomas, Andrew Hayes, Dirk Strauss, Martin Gore, Joost van den Oord, James Larkin, Richard Marais, Genome sequencing of mucosal melanomas reveals that they are driven by distinct mechanisms from cutaneous melanoma. The Journal of Pathology. ,vol. 230, pp. 261- 269 ,(2013) , 10.1002/PATH.4204
Sanjiv S. Agarwala, Alexander M. M. Eggermont, Steven O'Day, Jonathan S. Zager, Metastatic melanoma to the liver: A contemporary and comprehensive review of surgical, systemic, and regional therapeutic options Cancer. ,vol. 120, pp. 781- 789 ,(2014) , 10.1002/CNCR.28480
Omid Hamid, Robert Ilaria, Claus Garbe, Pascal Wolter, Michele Maio, Thomas E. Hutson, Ana Arance, Paul Lorigan, Jeeyun Lee, Axel Hauschild, Peter Mohr, Marjo Hahka-Kemppinen, Christopher Kaiser, P. Kellie Turner, Ilaria Conti, Jean-Jacques Grob, A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma Cancer. ,vol. 120, pp. 2016- 2024 ,(2014) , 10.1002/CNCR.28635
Scott S. Tykodi, John A. Thompson, Shailender Bhatia, Treatment of metastatic melanoma: an overview. Oncology. ,vol. 23, pp. 488- 496 ,(2009)
Madhavi C. Chander, Susan Band Horwitz, Prabu Devanesan, Forrest H. Anthony, Sharyn D. Baker, Nigel L. Webb, Philip A. Witman, Lifeng He, Matthews O. Bradley, S. Hemamalini, Charles S. Swindell, Tumor Targeting by Covalent Conjugation of a Natural Fatty Acid to Paclitaxel Clinical Cancer Research. ,vol. 7, pp. 3229- 3238 ,(2001)
David Berd, Michael J. Mastrangelo, Effect of Low Dose Cyclophosphamide on the Immune System of Cancer Patients: Reduction of T-Suppressor Function without Depletion of the CD8+ Subset Cancer Research. ,vol. 47, pp. 3317- 3321 ,(1987)